Project Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
177Lu-PSMA-617 225Ac abiraterone abiraterone acetate ADC ai in healthcare antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA BRCA2 cancer immunotherapy CAR-T CD3 clinical trial crispr darolutamide docetaxel drug repurposing enzalutamide EZH2 inhibitor HRR immunotherapy mcrpc metastatic hormone-sensitive prostate cancer mHSPC mRNA NEPC neuroendocrine prostate cancer oncolytic virus PARP1 PARP inhibitor Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data STEAP1 T-cell therapy
Latest Posts
- CRISPR Advances June 16, 2026
- Turning Prostate Cancer from Cold to Hot: How Tiny Silica Particles Kill Tumors and Wake Up the Immune System June 16, 2026
- Killing the Last 0.1%: Targeting Cancer Persister Cells June 15, 2026
- Phase III PrTK03 Trial Results: Aglatimagene Besadenovec (CAN-2409) Improves Survival in Localized Prostate Cancer June 15, 2026
Phase 2 Trial for The Combo Fasudil Hydrochloride Plus PD-1 Immune Checkpoint Blockade
/in Clinical Trial, Metastatic, Phase 2/by MaxA clinical trial at Zhongda Hospital in China is testing a combination of fasudil hydrochloride, a Rho-associated kinase (ROCK) inhibitor, with PD-1 immune checkpoint blockade in patients with advanced metastatic castration-resistant prostate cancer (mCRPC). This Phase II open-label trial enrolls patients aged 18 to 85 years who have progressed after at least one docetaxel-containing chemotherapy […]
Phase 1/2 Trial: Valemetostat Plus Darolutamide in mCRPC
/in Clinical Trial, Metastatic, Phase 1, Phase 2/by MaxA phase 1/2 clinical trial investigating valemetostat (DS-3201b), a dual EZH1/2 inhibitor, combined with darolutamide in metastatic castration-resistant prostate cancer (mCRPC) is going to start to recruit participants. This study aims to evaluate the safety, tolerability, and preliminary efficacy of the combination in men whose disease has progressed despite prior androgen receptor pathway inhibitors (ARPIs). […]
Phase 1 Trial: 177Lu-DGUL Plus Pembrolizumab (Keytruda) in mCRPC
/in Clinical Trial, Metastatic, Phase 1/by MaxA pivotal clinical trial is underway to evaluate the safety and efficacy of combining Lutetium (177Lu) DGUL radioligand therapy with pembrolizumab (Keytruda) for treating metastatic castration-resistant prostate cancer in patients who have progressed after androgen receptor-targeted therapies but have not yet received chemotherapy. The study enrolls men with prostate-specific membrane antigen (PSMA)-positive tumors, with disease […]
GTB-5550: a New Tri-Specific Natural Killer Cell Engager Moving To Clinical Trials
/in Clinical Trial, Metastatic, Phase 1/by MaxGTB-5550, a novel tri-specific natural killer (NK) cell engager drug designed to target the B7-H3 antigen has shown notable promise in advancing cancer immunotherapy for solid tumors, particularly prostate cancer and head and neck squamous cell carcinoma (HNSCC). This drug functions by simultaneously binding to CD16 on NK cells, engaging B7-H3 expressed on tumor cells, […]
Phase 3 Trial Evaluates Rezvilutamide vs Enzalutamide in mHSPC
/in Clinical Trial, Metastatic, Phase 3/by MaxA pivotal new Chinese phase 3 clinical trial is poised to begin recruiting patients with metastatic hormone-sensitive prostate cancer to compare two leading androgen receptor antagonists head-to-head: rezvilutamide (SHR3680) versus enzalutamide in mHSPC. This trial represents an important milestone in prostate cancer therapeutics by directly evaluating the efficacy and safety of these oral treatments in […]
Phase 2 Trial For a New Triplet Therapy: SHR3680 (Rezvilutamide), HS-20093 and SHR2554
/in Clinical Trial, Metastatic, Phase 2/by MaxThis Phase II study investigates the efficacy and safety of three investigational agents: SHR3680 (rezvilutamide), HS-20093, and SHR2554, aiming to enhance outcomes in metastatic prostate cancer through dual-pathway inhibition. SHR3680, a selective androgen receptor (AR) antagonist, represents the latest generation of hormonal therapy designed to inhibit the AR signaling axis, a critical driver of prostate […]
Phase 1 Trial for RAD 402, Terbium Based Radioligand for Metastatic or Locally Advanced or Prostate Cancer
/in Clinical Trial, Metastatic, Non-Metastatic, Phase 1, Phase 1/by MaxAustralian Human Research Ethics Committee has approved the initiation of a first‑in‑human Phase 1 therapeutic trial of RAD 402, a KLK3 (PSA)‑targeting monoclonal antibody labeled with terbium‑161 for patients with metastatic or locally advanced prostate cancer. The approval positions the program to begin site activation and enrollment in Australia, marking a notable milestone for a […]
Beyond the Primary Target: How DeepTarget Rewrites Mechanism Discovery in Cancer
/in Artificial Intelligence/by MaxThe modern small‑molecule rarely acts through a single, invariant target, and DeepTarget is a new computational framework that embraces this reality by mapping both direct and indirect anti‑cancer mechanisms across diverse cellular contexts. Developed by researchers at Sanford Burnham Prebys and collaborators, DeepTarget integrates large‑scale drug viability screens, genome‑wide CRISPR knockout data, and matched omics […]